CR10910A - INDAZOLS REPLACED WITH AMIDA AS POLY INHIBITORS (ADP-RIBOSA) POLYMERASE (PARP) - Google Patents

INDAZOLS REPLACED WITH AMIDA AS POLY INHIBITORS (ADP-RIBOSA) POLYMERASE (PARP)

Info

Publication number
CR10910A
CR10910A CR10910A CR10910A CR10910A CR 10910 A CR10910 A CR 10910A CR 10910 A CR10910 A CR 10910A CR 10910 A CR10910 A CR 10910A CR 10910 A CR10910 A CR 10910A
Authority
CR
Costa Rica
Prior art keywords
parp
adp
polymerase
inhibitors
poly
Prior art date
Application number
CR10910A
Other languages
Spanish (es)
Inventor
Philip Jones
Ontoria Jesus Maria Ontoria
Rita Scarpelli
Carsten Schultz-Fademrecht
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of CR10910A publication Critical patent/CR10910A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory discuses, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo and/or radiosensitizers for cancer treatment.
CR10910A 2007-01-10 2009-07-02 INDAZOLS REPLACED WITH AMIDA AS POLY INHIBITORS (ADP-RIBOSA) POLYMERASE (PARP) CR10910A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds

Publications (1)

Publication Number Publication Date
CR10910A true CR10910A (en) 2010-01-19

Family

ID=37809722

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10910A CR10910A (en) 2007-01-10 2009-07-02 INDAZOLS REPLACED WITH AMIDA AS POLY INHIBITORS (ADP-RIBOSA) POLYMERASE (PARP)

Country Status (21)

Country Link
CN (1) CN101578279B (en)
AT (1) ATE502933T1 (en)
CR (1) CR10910A (en)
DE (1) DE602008005711D1 (en)
DK (2) DK2109608T3 (en)
ES (3) ES2362214T3 (en)
GB (1) GB0700432D0 (en)
HN (1) HN2009001260A (en)
HU (1) HUE044513T2 (en)
LT (1) LT2805945T (en)
LU (1) LUC00072I2 (en)
ME (1) ME03481B (en)
MY (1) MY147789A (en)
NI (1) NI200900135A (en)
NZ (1) NZ578256A (en)
PE (1) PE20081558A1 (en)
PT (3) PT2805945T (en)
SI (2) SI2336120T1 (en)
TW (1) TWI528961B (en)
UA (1) UA97658C2 (en)
ZA (1) ZA200903898B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (en) * 2016-09-14 2017-03-15 陕西科技大学 A kind of synthetic method for preparing PARP inhibitor Niraparib
CN106432188A (en) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide
CN106432187A (en) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 Chiral resolution method of 2-[4-(-3-piperidyl)phenyl]-2H-indazole-7-formamide
CN106467513A (en) * 2016-09-30 2017-03-01 陕西科技大学 A kind of synthetic method preparing Niraparib
CN106632244A (en) * 2016-09-30 2017-05-10 陕西科技大学 A novel synthetic method for preparing an anticancer medicine Niraparib
CN108201537A (en) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 A kind of Ni Lapani sustained and controlled release medicaments composition and application thereof
AU2018246213A1 (en) * 2017-03-27 2019-11-07 Tesaro, Inc. Niraparib formulations
CN109081828B (en) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 Poly (ADP-ribose) polymerase inhibitor, preparation method and application
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
CN108084157A (en) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 A kind of synthetic method of Ni Lapani
CN108203404A (en) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
CN115611860A (en) * 2021-07-13 2023-01-17 上海博璞诺科技发展有限公司 Method for synthesizing nilapanib

Also Published As

Publication number Publication date
CN101578279A (en) 2009-11-11
DK2109608T3 (en) 2011-07-11
PT2805945T (en) 2019-06-06
SI2336120T1 (en) 2014-10-30
NZ578256A (en) 2011-12-22
TWI528961B (en) 2016-04-11
SI2109608T1 (en) 2011-07-29
PE20081558A1 (en) 2008-10-30
CN101578279B (en) 2013-07-17
NI200900135A (en) 2010-08-30
ATE502933T1 (en) 2011-04-15
GB0700432D0 (en) 2007-02-21
ES2362214T3 (en) 2011-06-29
ES2728199T3 (en) 2019-10-22
HUE044513T2 (en) 2019-10-28
DK2336120T3 (en) 2014-10-06
ES2509115T3 (en) 2014-10-17
TW200836731A (en) 2008-09-16
DE602008005711D1 (en) 2011-05-05
LUC00072I2 (en) 2018-07-04
LT2805945T (en) 2019-06-25
PT2109608E (en) 2011-05-30
HN2009001260A (en) 2012-03-26
PT2336120E (en) 2014-10-01
ZA200903898B (en) 2010-04-28
MY147789A (en) 2013-01-31
ME03481B (en) 2020-01-20
UA97658C2 (en) 2012-03-12

Similar Documents

Publication Publication Date Title
HN2009001260A (en) INDAZOLS REPLACED WITH AMIDA AS POLY INHIBITORS (ADPRIBOSE) POLYMERASE (PARP)
ECSP099484A (en) INDAZOLS REPLACED WITH AMIDA AS INHIBITORS OF
MX2010005070A (en) Pyridazinone derivatives as parp inhibitors.
WO2007138351A3 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
CL2021000566A1 (en) Processes for making 2 - ((3r, 5r, 6s) -5- (3-chlorophenyl) -6- (4-chlorophenyl) -1 - ((s) -1- (isopropylsulfonyl) -3-methylbutan-2- acid yl) -3-methyl-2-oxopiperidin-3-yl) acetic, intermediates and processes for making the intermediates, crystalline forms of the compound and the intermediates. (divisional application no. 2015003589)
CR20110077A (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
MX2012002179A (en) Heterocyclic oxime compounds.
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
MX339759B (en) Compounds for the treatment/prevention of ocular inflammatory diseases.
MX2012001838A (en) Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
DOP2011000081A (en) BENZAMIDA REPLACED AS LIGANDS OF THE CANABINOID RECEIVER
WO2008017883A3 (en) 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
MA32322B1 (en) Macrocyclic Urea and Sulphonamide Derivatives as Tafia Inhibitors
SA515360085B1 (en) Pyridine derivative and medicine
MX2014005538A (en) 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists.
GB201114389D0 (en) Novel compounds
TR201901937T4 (en) 8-methyl-1-phenyl-imidazole [1,5-a] pyrazine compounds.